0001209191-21-048385.txt : 20210727
0001209191-21-048385.hdr.sgml : 20210727
20210727205718
ACCESSION NUMBER: 0001209191-21-048385
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210722
FILED AS OF DATE: 20210727
DATE AS OF CHANGE: 20210727
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DENG FENG
CENTRAL INDEX KEY: 0001165399
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40632
FILM NUMBER: 211119508
MAIL ADDRESS:
STREET 1: SUITE 1701, 17/F HUTCHISON HOUSE
STREET 2: 10 HARCOURT ROAD, CENTRAL
CITY: HONG KONG
STATE: K3
ZIP: 00000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cytek Biosciences, Inc.
CENTRAL INDEX KEY: 0001831915
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 472547526
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 46107 LANDING PARKWAY
CITY: FREMONT
STATE: CA
ZIP: 94538
BUSINESS PHONE: (877) 922-9835
MAIL ADDRESS:
STREET 1: 46107 LANDING PARKWAY
CITY: FREMONT
STATE: CA
ZIP: 94538
FORMER COMPANY:
FORMER CONFORMED NAME: Cytek BioSciences, Inc.
DATE OF NAME CHANGE: 20201110
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-07-22
0
0001831915
Cytek Biosciences, Inc.
CTKB
0001165399
DENG FENG
2855 SAND HILL ROAD
MENLO PARK
CA
94025
1
0
0
0
Common Stock
2021-07-22
4
C
0
147933
A
147933
I
See footnote
Common Stock
2021-07-22
4
C
0
4168777
A
4168777
I
See footnote
Common Stock
2021-07-22
4
C
0
443800
A
443800
I
See footnote
Series A Preferred Stock
2021-07-22
4
C
0
147933
0.00
D
Common Stock
147933
0
I
See footnote
Series C Preferred Stock
2021-07-22
4
C
0
4168777
0.00
D
Common Stock
4168777
0
I
See footnote
Series D Preferred Stock
2021-07-22
4
C
0
443800
0.00
D
Common Stock
443800
0
I
See footnote
Each share of Preferred Stock automatically converted on a one-for-one basis into Common Stock upon the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.
Shares held directly by Northern Light Venture Capital V, Ltd. ("NLVC V"). Fund V serves as the nominee for each of Northern Light Venture Fund V, L.P., Northern Light Strategic Fund V, L.P. and Northern Light Partners Fund V, L.P (together, the "NLVC V Funds"). Northern Light Partners V, L.P., a Cayman Islands exempted limited liability partnership, is the general partner of the NLVC V Funds. NLVC V is the general partner of Northern Light Partners V, L.P. Feng Deng is the controlling shareholder of NLVC V and may be deemed to have voting and dispositive power with respect to the shares held by NLVC V.
/s/ Valerie Barnett, Attorney-in-Fact for Feng Deng
2021-07-27